Literature DB >> 17371987

Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy.

David Vermijlen1, Peter Ellis, Cordelia Langford, Anne Klein, Rosel Engel, Katharina Willimann, Hassan Jomaa, Adrian C Hayday, Matthias Eberl.   

Abstract

Human Vgamma9/Vdelta2 T cells comprise a small population of peripheral blood T cells that in many infectious diseases respond to the microbial metabolite, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), expanding to up to 50% of CD3(+) cells. This "transitional response," occurring temporally between the rapid innate and slower adaptive response, is widely viewed as proinflammatory and/or cytolytic. However, increasing evidence that different cytokines drive widely different effector functions in alphabeta T cells provoked us to apply cDNA microarrays to explore the potential pleiotropy of HMB-PP-activated Vgamma9/Vdelta2 T cells. The data and accompanying validations show that the related cytokines, IL-2, IL-4, or IL-21, each drive proliferation and comparable CD69 up-regulation but induce distinct effector responses that differ from prototypic alphabeta T cell responses. For example, the Th1-like response to IL-2 also includes expression of IL-5 and IL-13 that conversely are not induced by IL-4. The data identify specific molecules that may mediate gammadelta T cell effects. Thus, IL-21 induces a lymphoid-homing phenotype and high, unexpected expression of the follicular B cell-attracting chemokine CXCL13/BCA-1, suggesting a novel follicular B-helper-like T cell that may play a hitherto underappreciated role in humoral immunity early in infection. Such broad plasticity emphasizes the capacity of gammadelta T cells to influence the nature of the immune response to different challenges and has implications for the ongoing clinical application of cytokines together with Vgamma9/Vdelta2 TCR agonists.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371987      PMCID: PMC3915340          DOI: 10.4049/jimmunol.178.7.4304

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

Review 1.  [gamma][delta] cells: a right time and a right place for a conserved third way of protection.

Authors:  A C Hayday
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Biological insights into TCRgammadelta+ and TCRalphabeta+ intraepithelial lymphocytes provided by serial analysis of gene expression (SAGE).

Authors:  J Shires; E Theodoridis; A C Hayday
Journal:  Immunity       Date:  2001-09       Impact factor: 31.745

3.  Gamma delta T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells.

Authors:  W Pao; L Wen; A L Smith; A Gulbranson-Judge; B Zheng; G Kelsoe; I C MacLennan; M J Owen; A C Hayday
Journal:  Curr Biol       Date:  1996-10-01       Impact factor: 10.834

4.  Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation.

Authors:  K T Hall; L Boumsell; J L Schultze; V A Boussiotis; D M Dorfman; A A Cardoso; A Bensussan; L M Nadler; G J Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Interaction of the transcription factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental retardation syndrome.

Authors:  D Kumari; K Usdin
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

6.  Expression of cytokine receptors on follicular dendritic cells.

Authors:  K Yamada; M Yamakawa; Y Imai; M Tsukamoto
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

7.  Neurotrophin receptor-like protein immunoreactivity in human lymph nodes.

Authors:  O García-Suárez; J Hannestad; I Esteban; M Martínez del Valle; F J Naves; J A Vega
Journal:  Anat Rec       Date:  1997-10

8.  Activation of C-C beta-chemokines in human peripheral blood gammadelta T cells by isopentenyl pyrophosphate and regulation by cytokines.

Authors:  B Cipriani; G Borsellino; F Poccia; R Placido; D Tramonti; S Bach; L Battistini; C F Brosnan
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

9.  Transcript imaging of the development of human T helper cells using oligonucleotide arrays.

Authors:  L Rogge; E Bianchi; M Biffi; E Bono; S Y Chang; H Alexander; C Santini; G Ferrari; L Sinigaglia; M Seiler; M Neeb; J Mous; F Sinigaglia; U Certa
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

10.  Distinct gene expression profiles of human type 1 and type 2 T helper cells.

Authors:  H Hamalainen; H Zhou; W Chou; H Hashizume; R Heller; R Lahesmaa
Journal:  Genome Biol       Date:  2001-06-21       Impact factor: 13.583

View more
  68 in total

1.  The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy.

Authors:  Jessica Strid; Olga Sobolev; Biljana Zafirova; Bojan Polic; Adrian Hayday
Journal:  Science       Date:  2011-12-02       Impact factor: 47.728

Review 2.  Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity.

Authors:  Marc Bonneville; Rebecca L O'Brien; Willi K Born
Journal:  Nat Rev Immunol       Date:  2010-06-11       Impact factor: 53.106

Review 3.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

4.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

5.  Tec kinase Itk in gammadeltaT cells is pivotal for controlling IgE production in vivo.

Authors:  Martin Felices; Catherine C Yin; Yoko Kosaka; Joonsoo Kang; Leslie J Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-01       Impact factor: 11.205

6.  Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes.

Authors:  Gabriele Pizzolato; Hannah Kaminski; Marie Tosolini; Don-Marc Franchini; Fréderic Pont; Fréderic Martins; Carine Valle; Delphine Labourdette; Sarah Cadot; Anne Quillet-Mary; Mary Poupot; Camille Laurent; Loic Ysebaert; Serena Meraviglia; Francesco Dieli; Pierre Merville; Pierre Milpied; Julie Déchanet-Merville; Jean-Jacques Fournié
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-22       Impact factor: 11.205

Review 7.  Multifunctional immune responses of HMBPP-specific Vγ2Vδ2 T cells in M. tuberculosis and other infections.

Authors:  Zheng W Chen
Journal:  Cell Mol Immunol       Date:  2012-11-12       Impact factor: 11.530

8.  Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.

Authors:  Marlène Brandes; Katharina Willimann; Gilles Bioley; Nicole Lévy; Matthias Eberl; Ming Luo; Robert Tampé; Frédéric Lévy; Pedro Romero; Bernhard Moser
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

9.  Human cytomegalovirus elicits fetal gammadelta T cell responses in utero.

Authors:  David Vermijlen; Margreet Brouwer; Catherine Donner; Corinne Liesnard; Marie Tackoen; Michel Van Rysselberge; Nicolas Twité; Michel Goldman; Arnaud Marchant; Fabienne Willems
Journal:  J Exp Med       Date:  2010-04-05       Impact factor: 14.307

10.  Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.

Authors:  Daniel V Correia; Francisco d'Orey; Bruno A Cardoso; Telma Lança; Ana R Grosso; Ana deBarros; Leila R Martins; João T Barata; Bruno Silva-Santos
Journal:  PLoS One       Date:  2009-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.